Want to see AU:NUC full AI Analyst Report?
Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.09
▼(-26.67% Downside)
Action:Upgraded
Date:08/29/26
The score is primarily constrained by weak financial performance: ongoing losses, significant cash burn, margin deterioration in 2026, and higher leverage. Technicals add some support from short-term strength, but overbought signals and a longer-term downtrend limit the contribution. Valuation is also capped due to negative earnings and no dividend yield.
Positive Factors
Revenue Growth and Scale
The strong multi-year revenue increase indicates growing demand and improving operating scale. Sustained expansion could provide a broader base for fixed-cost absorption and eventual margin recovery if the company can control product and operating costs.
Negative Factors
Severe Margin Deterioration
The sharp gross-margin contraction materially weakens the economics of the business and shows that revenue growth is not currently converting into profitability. Unless pricing, sourcing, or product mix improves, future scale may add sales without creating durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Scale
The strong multi-year revenue increase indicates growing demand and improving operating scale. Sustained expansion could provide a broader base for fixed-cost absorption and eventual margin recovery if the company can control product and operating costs.
Read all positive factors
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.33M
Dividend YieldN/A
Average Volume (3M)94.00
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth11.96%
EPS Growth-81.99%
CountryAU
Employees100
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.05
Shares Outstanding156,818,770
10 Day Avg. Volume283
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.97
Price to Sales (P/S)0.45
P/FCF Ratio-1.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$28.30M
Nuchev Pty Ltd Business Overview & Revenue Model
Company Description
Nuchev Limited functions as a specialized health and nutrition company, responsible for the production, marketing, and distribution of infant formula and various nutritional items derived from goat milk. Its products are sold to consumers across A...
Nuchev Pty Ltd Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.68M | 22.94M | 11.34M | 8.79M | 9.72M |
| Gross Profit | 3.19M | 10.86M | 3.63M | 1.90M | 2.78M |
| EBITDA | -4.76M | -3.73M | -7.18M | -8.57M | -10.88M |
| Net Income | -7.39M | -3.82M | -7.32M | -8.81M | -11.11M |
Balance Sheet | |||||
| Total Assets | 19.60M | 17.39M | 20.09M | 15.32M | 17.75M |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 3.61M | 7.61M | 7.49M | 5.13M |
| Total Debt | 4.19M | 392.63K | 322.85K | 284.14K | 154.12K |
| Total Liabilities | 13.67M | 6.16M | 5.34M | 2.51M | 1.92M |
| Stockholders Equity | 5.93M | 11.23M | 14.75M | 12.82M | 15.83M |
Cash Flow | |||||
| Free Cash Flow | -6.66M | -3.93M | -3.74M | -3.38M | -11.62M |
| Operating Cash Flow | -6.64M | -3.74M | -3.73M | -3.26M | -11.61M |
| Investing Cash Flow | -83.22K | -138.16K | -2.19M | -126.83K | -914.20K |
| Financing Cash Flow | 5.27M | -115.53K | 6.06M | 5.78M | -118.28K |
Nuchev Pty Ltd Technical Analysis
Negative
0.12
Price Trends
0.08
Negative
0.10
Negative
0.12
Negative
Market Momentum
>-0.01
Negative
44.19
Neutral
-14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.19 is Neutral, neither overbought nor oversold. The STOCH value of -14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NUC.
Nuchev Pty Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$145.29M | 16.35 | 12.22% | 2.27% | 27.60% | 96.31% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | AU$33.25M | -0.51 | 13.40% | ― | 8.82% | 55.22% | |
48 Neutral | AU$78.68M | -18.27 | -11.08% | ― | 9.08% | -183.87% | |
46 Neutral | AU$13.33M | -1.79 | -88.51% | ― | 11.96% | -81.99% | |
43 Neutral | AU$14.17M | -4.47 | -12.90% | ― | 0.46% | 46.48% | |
39 Underperform | AU$6.99M | -0.01 | 226.76% | ― | -32.83% | 83.37% |
* Consumer Defensive Sector Average
AU:NUC
Nuchev Pty Ltd
0.09
-0.06
-43.33%
AU:NOU
Noumi Limited
0.12
-0.04
-25.00%
AU:AHF
Australian Dairy Nutritionals Group
0.02
-0.02
-57.14%
AU:BUB
Bubs Australia Ltd.
0.09
-0.07
-41.88%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
16.67%
AU:CLV
Clover Corporation Limited
0.89
0.33
60.62%
Nuchev Pty Ltd Corporate Events
Nuchev Enters Women’s Health with Kuci Rollout Through Chemist Warehouse
Aug 28, 2026
Nuchev has signed an exclusive distribution agreement with Biomera Biotics to support the national rollout of the Kuci women’s health probiotic range through Chemist Warehouse, marking its entry into the women’s health segment. The sci...
Nuchev Outlines FY26 Corporate Governance Framework and ASX Compliance
Aug 27, 2026
Nuchev Limited has issued its FY26 Corporate Governance Statement, reaffirming the board’s commitment to high governance standards and regular review of its framework in line with evolving best practice. The statement outlines how the compan...
Nuchev Refocuses Strategy on Nutrition Platform and Financial Discipline in FY26
Aug 27, 2026
Nuchev Limited has released its FY26 full-year results for the year ended 30 June 2026, highlighting a strategic shift towards building a broader nutrition and wellness platform. The company is now concentrating on improving conversion, margins an...
Nuchev lifts revenue but margins and cash pressures deepen in FY26
Aug 27, 2026
Nuchev reported full-year 2026 group revenue of $25.7 million, up 12% on the prior year, driven by solid performance in its domestic Oli6® goat nutrition range and a growing contribution from Brauer after shifting to a broader distribution mo...
Nuchev lifts revenue but posts deeper loss as asset backing weakens
Aug 27, 2026
Nuchev Limited reported a 12.0% rise in revenues from ordinary activities to $25.7 million for the year ended 30 June 2026, but its loss after tax widened sharply to $7.4 million, up 93.2% on the prior year. The group again withheld dividends, ref...
Nuchev Options Lapse, Streamlining Capital Structure
Aug 4, 2026
Nuchev Limited has confirmed the lapse of 7,407,700 options with an exercise price of $0.36 that expired on July 30, 2026. The cessation of these unexercised options reduces the company’s potential future dilution, modestly simplifying its c...
Nuchev lifts FY26 revenue as domestic Oli6 growth offsets weak international markets
Jul 27, 2026
Nuchev reported group sales revenue of $24.1m for FY26, up 4.6% year on year, with June quarter revenue rebounding to $7.4m and June monthly revenue of $2.9m, a 26.7% increase on the prior period. Domestic Oli6 retail remained a key growth driver,...
Nuchev relocates Melbourne head office with operations unchanged
Jun 30, 2026
Nuchev Limited has updated its registered office and principal place of business to Level 9B, 5 Bowen Crescent in Melbourne, effective 2 July 2026, while keeping all other contact details unchanged. The move reflects an administrative change to th...
Nuchev to Release 22.4 Million Escrowed Shares to Market
Jun 22, 2026
Nuchev Limited has announced that 22,435,898 fully paid ordinary shares will be released from ASX-imposed escrow on 28 June 2026, returning these securities to regular trading conditions. As the shares are already quoted on the exchange, the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.